Amneal touts 39 retail, injectable product launches in 2023

2023 was a productive year for Amneal. The company shared that it launched 39 new retail and injectable medicines in 2023, compared to 26 new launches in 2022.

In the fourth quarter of 2023, Amneal launched 13 new products, including five injectables. New injectable products include potassium phosphate vials, tranexamic acid and esmolol intravenous bags. These launches provide a strong foundation for higher injectable revenues going forward. In addition, Amneal launched several key new retail products in the fourth quarter, including spironolactone suspension with 180-day exclusivity, valsartan and hydrochlorothiazide tablets and icosapent capsules.

[Read more: Amneal touts 26 generic new product launches in 2022]

“We are pleased to have brought an impressive number of new products to market in 2023,” said  Srinivas Kone, senior vice president, generics research and development. “Our R&D portfolio prioritizes complex and high-value products that provide better access to affordable medicines for providers and patients.”

[Read more: Amneal debuts 2 generics]